Incretins in the Therapy of Diabetic Kidney Disease

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Nov 27

PMID 34830194

Citations 6

Authors

Agnieszka Przezak

Weronika Bielka

Andrzej Pawlik

Affiliations

Soon will be listed here.

Abstract

Diabetic kidney disease is a microvascular complication that occurs in patients with diabetes. It is strongly associated with increased risk of kidney replacement therapy and all-cause mortality. Incretins are peptide hormones derived from the gastrointestinal tract, that besides causing enhancement of insulin secretion after oral glucose intake, participate in many other metabolic processes. Antidiabetic drug classes, such as dipeptidyl peptidase 4 inhibitors and glucagon-like peptide receptor agonists, which way of action is based on incretins facility, not only show glucose-lowering properties but also have nephroprotective functions. The aim of this article is to present the latest information about incretin-based therapy and its influence on diabetic kidney disease appearance and progression, point its potential mechanisms of kidney protection and focus on future therapeutic possibilities bound with these two antidiabetic drug classes.

Citing Articles

A Specific Collagen Hydrolysate Improves Postprandial Glucose Tolerance in Normoglycemic and Prediabetic Mice and in a First Proof of Concept Study in Healthy, Normoglycemic and Prediabetic Humans.

Grasset E, Briand F, Virgilio N, Schon C, Wilhelm M, Cudennec B Food Sci Nutr. 2024; 12(11):9607-9620.

PMID: 39619994 PMC: 11606891. DOI: 10.1002/fsn3.4538.

Incretin-based therapy: a new horizon in diabetes management.

Zarei M, Sahebi Vaighan N, Farjoo M, Talebi S, Zarei M J Diabetes Metab Disord. 2024; 23(2):1665-1686.

PMID: 39610543 PMC: 11599551. DOI: 10.1007/s40200-024-01479-3.

Molecular Characterization and Functional Analysis of the Dipeptidyl Peptidase IV from Venom of the Ectoparasitoid .

Wu C, Yang C, Wang Y, Wang J, Zhu J Toxins (Basel). 2023; 15(5).

PMID: 37235347 PMC: 10222045. DOI: 10.3390/toxins15050311.

Sitagliptin Mitigates Diabetic Nephropathy in a Rat Model of Streptozotocin-Induced Type 2 Diabetes: Possible Role of PTP1B/JAK-STAT Pathway.

Al-Qabbaa S, Qaboli S, Alshammari T, Alamin M, Alrajeh H, Almuthnabi L Int J Mol Sci. 2023; 24(7).

PMID: 37047505 PMC: 10095069. DOI: 10.3390/ijms24076532.

Links between Metabolic Syndrome and Hypertension: The Relationship with the Current Antidiabetic Drugs.

Stanciu S, Rusu E, Miricescu D, Radu A, Axinia B, Vrabie A Metabolites. 2023; 13(1).

PMID: 36677012 PMC: 9863091. DOI: 10.3390/metabo13010087.

References

Yang H, Li H, Wang Z, Shi Y, Jiang G, Zeng F . Exendin-4 ameliorates renal ischemia-reperfusion injury in the rat. J Surg Res. 2013; 185(2):825-32. DOI: 10.1016/j.jss.2013.06.042. View

Barros R, Gabbi C, Morani A, Warner M, Gustafsson J . Participation of ERalpha and ERbeta in glucose homeostasis in skeletal muscle and white adipose tissue. Am J Physiol Endocrinol Metab. 2009; 297(1):E124-33. DOI: 10.1152/ajpendo.00189.2009. View

Twarog C, Fattah S, Heade J, Maher S, Fattal E, Brayden D . Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C). Pharmaceutics. 2019; 11(2). PMC: 6410172. DOI: 10.3390/pharmaceutics11020078. View

Tonneijck L, Muskiet M, Smits M, Hoekstra T, Kramer M, Danser A . Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial. Diabetes Obes Metab. 2017; 19(12):1669-1680. DOI: 10.1111/dom.12985. View

Yaribeygi H, Sathyapalan T, Sahebkar A . Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity. Life Sci. 2019; 234:116776. DOI: 10.1016/j.lfs.2019.116776. View

Amatruda M, Gembillo G, Giuffrida A, Santoro D, Conti G . The Aggressive Diabetic Kidney Disease in Youth-Onset Type 2 Diabetes: Pathogenetic Mechanisms and Potential Therapies. Medicina (Kaunas). 2021; 57(9). PMC: 8467670. DOI: 10.3390/medicina57090868. View

Okemah J, Peng J, Quinones M . Addressing Clinical Inertia in Type 2 Diabetes Mellitus: A Review. Adv Ther. 2018; 35(11):1735-1745. PMC: 6223992. DOI: 10.1007/s12325-018-0819-5. View

Jha J, Banal C, Okabe J, Gray S, Hettige T, Chow B . NADPH Oxidase Nox5 Accelerates Renal Injury in Diabetic Nephropathy. Diabetes. 2017; 66(10):2691-2703. DOI: 10.2337/db16-1585. View

Bergmann N, Lund A, Gasbjerg L, Jorgensen N, Jessen L, Hartmann B . Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes. J Clin Endocrinol Metab. 2019; 104(7):2953-2960. DOI: 10.1210/jc.2019-00008. View

10.

Vilsboll T . Liraglutide: a new treatment for type 2 diabetes. Drugs Today (Barc). 2009; 45(2):101-13. DOI: 10.1358/dot.2009.45.2.1336104. View

11.

Ofosu W, Mohamed D, Corcoran O, Ojo O . The Role of Oestrogen Receptor Beta (ERβ) in the Aetiology and Treatment of Type 2 Diabetes Mellitus. Curr Diabetes Rev. 2018; 15(2):100-104. DOI: 10.2174/1573399814666180119141836. View

12.

Pratley R, Aroda V, Lingvay I, Ludemann J, Andreassen C, Navarria A . Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018; 6(4):275-286. DOI: 10.1016/S2213-8587(18)30024-X. View

13.

Bethel M, Mentz R, Merrill P, Buse J, Chan J, Goodman S . Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. Diabetes Care. 2019; 43(2):446-452. PMC: 7411285. DOI: 10.2337/dc19-1065. View

14.

Li W, Cui M, Wei Y, Kong X, Tang L, Xu D . Inhibition of the expression of TGF-β1 and CTGF in human mesangial cells by exendin-4, a glucagon-like peptide-1 receptor agonist. Cell Physiol Biochem. 2012; 30(3):749-57. DOI: 10.1159/000341454. View

15.

Girardi A, Knauf F, Demuth H, Aronson P . Role of dipeptidyl peptidase IV in regulating activity of Na+/H+ exchanger isoform NHE3 in proximal tubule cells. Am J Physiol Cell Physiol. 2004; 287(5):C1238-45. DOI: 10.1152/ajpcell.00186.2004. View

16.

Ohnuma K, Dang N, Morimoto C . Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol. 2008; 29(6):295-301. DOI: 10.1016/j.it.2008.02.010. View

17.

Holt M, Richards J, Cook D, Brierley D, Williams D, Reimann F . Preproglucagon Neurons in the Nucleus of the Solitary Tract Are the Main Source of Brain GLP-1, Mediate Stress-Induced Hypophagia, and Limit Unusually Large Intakes of Food. Diabetes. 2018; 68(1):21-33. PMC: 6314470. DOI: 10.2337/db18-0729. View

18.

Amori R, Lau J, Pittas A . Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007; 298(2):194-206. DOI: 10.1001/jama.298.2.194. View

19.

Ahren B, Hughes T . Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing.... Endocrinology. 2004; 146(4):2055-9. DOI: 10.1210/en.2004-1174. View

20.

Alicic R, Neumiller J, Johnson E, Dieter B, Tuttle K . Sodium-Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease. Diabetes. 2019; 68(2):248-257. DOI: 10.2337/dbi18-0007. View